Purpose: Chronic myeloid leukaemia (CML) patients on long-term tyrosine kinase inhibitor (TKI) therapy are susceptible to drug-related problems (DRPs). This study aimed to evaluate the acceptability and outcomes of pharmacist-led interventions on DRPs encountered by CML patients.
Methods: This study included participants from the intervention arm of a randomised controlled trial
Journal of Oncology Pharmacy Practice 2021;27(7):1644-1656. /
Tan BK, Chua SS, Chen L-C, Chang KM, et al.
Background and objective: The objective of this study was to estimate the lifetime costs of patients receiving treatment for follicular lymphoma (FL) in the United States.
Methods: A Markov model was programmed in hēRo3 with a 6-month cycle length, 35-year time horizon (lifetime projection), and health states for line of treatment,
PharmacoEconomics 2021; 39:1163–1183. /
Eichten C, Ma Q, Delea TE. et al.
Background: Medication reconciliation prevents medication errors at care transition points. This process improves communication with general practitioners regarding the reasons for therapeutic changes, allowing those changes to be maintained after hospital discharge.
Objective: To investigate the impact of medication reconciliation in geriatrics on the sustainability of therapeutic optimization after hospital discharge.
PharmacoEconomics 2021; 39: 1163–1183. /
Montaleytang M, Correard F, Spiter C, et al.
The SARS-CoV-2 messenger RNA (mRNA) vaccines BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) have each shown more than 90% efficacy in preventing COVID-19 illness but, to our knowledge, humoral immune responses have not been compared directly.
Methods: Health care workers at a tertiary care center (Ziekenhuis Oost-Limburg, Belgium) who were scheduled for vaccination
JAMA 2021;326(15):1533–1535. /
Steensels D, Pierlet N, Penders J, et al.
Background: ML-2 (NCT01958021) is a randomized phase III clinical trial investigating first-line (1L) RIB, a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i), + letrozole (LET) vs placebo (PBO) + LET in postmenopausal pts with HR+/HER2− ABC. ML-2 previously reported a statistically significant improvement in progression-free survival (PFS; primary endpoint) with RIB +
Annals of Oncology 2021; 32 (suppl_5): S1283-S1346. /
Hortobagyi GN, Stemmer SM, Burris HA, et al.
Background: Despite the high efficacy of the BNT162b2 messenger RNA vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), rare breakthrough infections have been reported, including infections among health care workers. Data are needed to characterize these infections and define correlates of breakthrough and infectivity.
Methods: At the largest medical center
N Engl J Med 2021; 385:1474-1484 /
Bergwerk M, Gonen T, Lustig Y, et al.
Background: Debate over the viability of the current commercial research and development (R&D) model is ongoing. A controversial theme is the cost of bringing a new molecular entity (NME) to market.
Objective: Our aim was to evaluate the range and suitability of published R&D cost estimates as to the degree to
PharmacoEconomics 2021; 39:1243–1269. /
Schlander M, Hernandez-Villafuerte K, Cheng CY, et al.
Background: The WHO Essential Medicines List (EML) identifies priority medicines that are most important to public health. Over time, the EML has included an increasing number of cancer medicines. We aimed to investigate whether the cancer medicines in the EML are aligned with the priority medicines of frontline oncologists worldwide,
The Lancet Oncology 2021; 22(10):1367-77. /
Fundytus A, Sengar M, Lombe D, et al.
The Oncology Pharmacy Team (OPT), consisting of specialty-trained pharmacists and/or pharmacy technicians, is an integral component of the multidisciplinary healthcare team (MHT) involved with all aspects of cancer patient care.
The OPT fosters quality patient care, safety, and local regulatory compliance. The International Society of Oncology Pharmacy Practitioners (ISOPP) developed this
Oncology Pharmacy Practice 2021;27(4):785-801. /
Holle LM, Bilse T, Alabelewe RM, et al.
Background: Beta thalassemia patients, post-bone marrow transplant, and leukemia patients require long term therapy with an intense care follow-up especially for pediatric hematology–oncology origin. Emergence of side effects and noncompliance to therapy lead to reduced efficacy of medicines resulting in relapse of diseases. There is an increasing fact to support
Journal of Oncology Pharmacy Practice 2021;27(4):815-820. /
Ali K, Al-Quteimat O, Naseem R, et al.